BMS' Experimental RA Drug Orencia Is Effective, Say FDA Scientists

Drug Industry Daily
KEYWORDS FDA / Rx
A A

Bristol-Myers Squibb’s (BMS) rheumatoid arthritis (RA) drug candidate Orencia is effective in treating patients with moderately to severely active RA, according to an FDA review of the product. Analysts predict the drug could reach blockbuster status.

To View This Article:

Login

Subscribe To Drug Industry Daily